argenx SE
F:1AEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
argenx SE
F:1AEA
|
NL |
|
A
|
Albis Leasing AG
XMUN:ALG
|
DE |
Intrinsic Value
The intrinsic value of 
argenx SE (1AEA) under the Base Case is 761.78 EUR per share.
Compared with the current market price of 780 EUR, the stock appears
Overvalued by 2% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What argenx Does
argenx is a biotechnology company that develops antibody-based medicines for serious autoimmune diseases, where the body attacks its own tissues. Its best-known product is VYVGART, a prescription therapy used by specialist doctors and hospitals to treat certain immune disorders. The company also has a pipeline of follow-on drug candidates built around the same antibody engineering platform.
- Headquarters
- Netherlands NL
- Employees
- 1 863
- IPO date
- Jul 10, 2014
argenx has a narrow economic moat
Patents covering Vyvgart’s active medicine and its uses prevent rivals from freely copying argenx’s main treatment. This protects its profits without shutting out competing medicines such as UCB’s Rystiggo and Johnson & Johnson’s Imaavy.
Read the full moat analysis
Earnings Waterfall
argenx SE
The intrinsic value for argenx SE (1AEA) under the Base Case is 761.78 EUR.
Compared with the current market price of 780 EUR, the stock appears Overvalued by 2% .